Mats Grahn, CEO of Immunovia, today announced that he has sold 48,000 shares of Immunovia, corresponding to 11.6% of his holding in Immunovia. The shares have been sold at a price of SEK 168 per share. The buyer is a Swedish institutional investor. The reason for the sale is for private real estate business.
With the transaction, Immunovia today announced a change in the company’s ownership structure. Mats Grahn’s ownership has been reduced from 2.11% to 1.87% with the transaction.
Furthermore, Mats Grahn has committed to new lock up restrictions of 12 months from today’s date.
For more information, please contact:
Julie Silber
Investor Relations Director, Immunovia
Tel.: +46-79-3486277
Email: julie.silber@immunovia.com
This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through the agency of the contact person
set out above, at 4.40 p.m. (CET) on June 19, 2019.
About Immunovia Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
###
Immunovia Press Release
